Quinn Opportunity Partners Has Upped Facebook (FB) Holding By $1.53 Million; 6 Analysts Covering pSivida Corp. (PSDV)

February 20, 2018 - By Vivian Park

Quinn Opportunity Partners Llc increased Facebook Inc (FB) stake by 94.74% reported in 2017Q3 SEC filing. Quinn Opportunity Partners Llc acquired 9,000 shares as Facebook Inc (FB)’s stock rose 10.88%. The Quinn Opportunity Partners Llc holds 18,500 shares with $3.16M value, up from 9,500 last quarter. Facebook Inc now has $513.69B valuation. The stock decreased 0.30% or $0.53 during the last trading session, reaching $176.83. About 13.57 million shares traded. Facebook, Inc. (NASDAQ:FB) has risen 26.75% since February 20, 2017 and is uptrending. It has outperformed by 10.05% the S&P500.

Among 6 analysts covering pSivida (NASDAQ:PSDV), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. pSivida had 19 analyst reports since October 15, 2015 according to SRatingsIntel. The stock of pSivida Corp. (NASDAQ:PSDV) has “Buy” rating given on Friday, December 15 by H.C. Wainwright. H.C. Wainwright maintained pSivida Corp. (NASDAQ:PSDV) on Tuesday, July 11 with “Buy” rating. On Wednesday, June 14 the stock rating was maintained by Northland Capital with “Buy”. Ladenburg maintained it with “Buy” rating and $12.5000 target in Tuesday, June 13 report. H.C. Wainwright maintained pSivida Corp. (NASDAQ:PSDV) on Wednesday, November 8 with “Buy” rating. On Wednesday, September 27 the stock rating was maintained by H.C. Wainwright with “Buy”. H.C. Wainwright maintained pSivida Corp. (NASDAQ:PSDV) rating on Tuesday, January 9. H.C. Wainwright has “Buy” rating and $5.0 target. The company was maintained on Tuesday, May 30 by H.C. Wainwright. The company was initiated on Thursday, October 15 by FBR Capital. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, September 12. See pSivida Corp. (NASDAQ:PSDV) latest ratings:

08/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $5.0 Maintain
05/02/2018 Broker: FBR Capital Rating: Buy New Target: $5.0 Initiate
09/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $5.0 Maintain
15/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.0 Maintain
04/12/2017 Broker: FBR Capital Rating: Buy New Target: $5.0
08/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.0 Maintain
08/11/2017 Broker: Laidlaw Rating: Buy New Target: $5 Initiates Coverage On
11/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.0 Maintain
27/09/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.0 Maintain
12/09/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.0 Maintain

Among 54 analysts covering Facebook (NASDAQ:FB), 50 have Buy rating, 2 Sell and 2 Hold. Therefore 93% are positive. Facebook had 236 analyst reports since July 21, 2015 according to SRatingsIntel. Oppenheimer maintained the shares of FB in report on Thursday, November 2 with “Outperform” rating. The rating was maintained by Cantor Fitzgerald with “Buy” on Friday, May 26. The firm has “Buy” rating by Piper Jaffray given on Wednesday, October 11. The stock has “Outperform” rating by Wedbush on Thursday, April 28. The rating was reinitiated by Wedbush with “Outperform” on Thursday, October 1. Canaccord Genuity maintained the stock with “Buy” rating in Monday, October 30 report. The stock of Facebook, Inc. (NASDAQ:FB) earned “Sell” rating by Jyske Bank on Friday, October 30. The rating was maintained by Aegis Capital with “Buy” on Wednesday, July 26. KeyBanc Capital Markets maintained the shares of FB in report on Thursday, November 2 with “Overweight” rating. The firm has “Buy” rating given on Wednesday, June 7 by RBC Capital Markets.

Since August 21, 2017, it had 0 insider purchases, and 33 insider sales for $512.57 million activity. On Monday, February 12 the insider Zuckerberg Mark sold $69.56 million. 750 shares were sold by Stretch Colin, worth $134,821. Shares for $2.77M were sold by Cox Christopher K. 16,298 shares were sold by FISCHER DAVID B., worth $2.75M on Thursday, August 24. On Tuesday, January 9 Schroepfer Michael Todd sold $7.14M worth of Facebook, Inc. (NASDAQ:FB) or 38,017 shares. Koum Jan sold 640,754 shares worth $109.70 million. Another trade for 55,000 shares valued at $9.75M was made by Sandberg Sheryl on Wednesday, February 14.

Quinn Opportunity Partners Llc decreased Class A stake by 74,725 shares to 26,663 valued at $335,000 in 2017Q3. It also reduced Guess Inc (NYSE:GES) stake by 146,797 shares and now owns 44,005 shares. Gaming And Leisure Propertie (NASDAQ:GLPI) was reduced too.

Investors sentiment decreased to 1.15 in Q3 2017. Its down 0.25, from 1.4 in 2017Q2. It worsened, as 53 investors sold FB shares while 618 reduced holdings. 128 funds opened positions while 644 raised stakes. 1.63 billion shares or 0.88% more from 1.62 billion shares in 2017Q2 were reported. Sandy Spring Financial Bank invested in 31,505 shares. Westfield Cap Mgmt Company LP stated it has 1.63 million shares or 2.14% of all its holdings. Royal Comml Bank Of Canada holds 0.56% or 6.77M shares in its portfolio. Boys Arnold & stated it has 6,761 shares. State Board Of Administration Of Florida Retirement holds 1.57% of its portfolio in Facebook, Inc. (NASDAQ:FB) for 3.36M shares. Lau Associates Ltd Liability holds 1.32% of its portfolio in Facebook, Inc. (NASDAQ:FB) for 9,950 shares. Jolley Asset Mgmt Lc invested 0.01% in Facebook, Inc. (NASDAQ:FB). Albion Fincl Gru Ut has invested 2.25% of its portfolio in Facebook, Inc. (NASDAQ:FB). Perigon Wealth Management Limited Liability Corporation reported 1.9% in Facebook, Inc. (NASDAQ:FB). Ipg Advisors Limited Liability reported 3.85% stake. Contravisory Investment Management Inc owns 49,586 shares. Mengis holds 3,675 shares or 0.42% of its portfolio. Tuttle Tactical Management Limited Liability owns 10,579 shares. Cetera Advisors Lc holds 0.38% or 36,659 shares in its portfolio. Us Bancshares De holds 0.39% in Facebook, Inc. (NASDAQ:FB) or 712,186 shares.

Investors sentiment decreased to 0.62 in Q3 2017. Its down 0.61, from 1.23 in 2017Q2. It worsened, as 3 investors sold pSivida Corp. shares while 10 reduced holdings. 2 funds opened positions while 6 raised stakes. 4.35 million shares or 24.39% less from 5.76 million shares in 2017Q2 were reported. Citadel Ltd Llc has invested 0% in pSivida Corp. (NASDAQ:PSDV). California Pub Employees Retirement System owns 64,900 shares. Panagora Asset reported 0% of its portfolio in pSivida Corp. (NASDAQ:PSDV). Goldman Sachs Gp Incorporated reported 0% stake. 137,481 are owned by Geode Limited Liability. Comml Bank Of New York Mellon stated it has 0% in pSivida Corp. (NASDAQ:PSDV). Bridgeway Cap holds 0% in pSivida Corp. (NASDAQ:PSDV) or 133,900 shares. Deutsche Bankshares Ag invested 0% in pSivida Corp. (NASDAQ:PSDV). Morgan Stanley holds 274,333 shares or 0% of its portfolio. Finemark National Bank & holds 0.01% of its portfolio in pSivida Corp. (NASDAQ:PSDV) for 71,800 shares. Art Advsr Lc invested in 0% or 48,270 shares. Matrix Asset Advisors Ny, New York-based fund reported 37,500 shares. Creative Planning reported 35,000 shares. Utd Capital Advisers Ltd Llc invested 0% of its portfolio in pSivida Corp. (NASDAQ:PSDV). Bard Associates invested in 84,459 shares.

The stock increased 0.91% or $0.01 during the last trading session, reaching $1.11. About 159,170 shares traded. pSivida Corp. (NASDAQ:PSDV) has declined 20.28% since February 20, 2017 and is downtrending. It has underperformed by 36.98% the S&P500.

pSivida Corp. develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the United States and the United Kingdom. The company has market cap of $50.24 million. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior segment uveitis. It currently has negative earnings. The firm is also developing Durasert, an injectable, sustained-release micro-insert, which is in Phase III clinical trials for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: